Phio Financial Statements From 2010 to 2024

PHIO Stock  USD 0.69  0.01  0.72%   
Phio Pharmaceuticals financial statements provide useful quarterly and yearly information to potential Phio Pharmaceuticals Corp investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Phio Pharmaceuticals financial statements helps investors assess Phio Pharmaceuticals' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Phio Pharmaceuticals' valuation are summarized below:
Gross Profit
-7 M
Market Capitalization
3.1 M
Enterprise Value Revenue
172.2001
Earnings Share
(2.52)
We have found one hundred twenty available trending fundamental ratios for Phio Pharmaceuticals Corp, which can be analyzed and compared to other ratios and to its competitors. Self-guided Investors are advised to check out Phio Pharmaceuticals' recent fundamentals against the trend between 2010 and 2024 to make sure the company can sustain itself down the road. As of the 25th of June 2024, Market Cap is likely to drop to about 1.5 M. In addition to that, Enterprise Value is likely to drop to about (7.2 M)

Phio Pharmaceuticals Total Revenue

0.0

Check Phio Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Phio Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 115.8 K, Interest Expense of 211.3 K or Other Operating Expenses of 9 M, as well as many indicators such as Price To Sales Ratio of 275, Dividend Yield of 0.0 or PTB Ratio of 0.19. Phio financial statements analysis is a perfect complement when working with Phio Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Phio Pharmaceuticals Correlation against competitors.

Phio Pharmaceuticals Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets12.4 M9.4 M10.7 M
Slightly volatile
Short and Long Term Debt Total33.2 K35 K400.6 K
Slightly volatile
Other Current Liabilities1.1 M942 KM
Pretty Stable
Total Current Liabilities2.2 M1.6 MM
Slightly volatile
Property Plant And Equipment Net37 K39 K271.9 K
Very volatile
Current Deferred Revenue1.5 M1.4 M910.6 K
Slightly volatile
Accounts Payable647.1 K657 K578.8 K
Slightly volatile
Cash10.8 M8.5 M9.3 M
Slightly volatile
Non Current Assets Total39.9 K42 K294.9 K
Very volatile
Cash And Short Term Investments11.5 M8.5 M9.9 M
Slightly volatile
Net Receivables477.6 K537.3 K585.1 K
Slightly volatile
Common Stock Total Equity8559003.8 K
Slightly volatile
Common Stock Shares Outstanding2.2 M2.1 M461 K
Slightly volatile
Liabilities And Stockholders Equity12.4 M9.4 M10.7 M
Slightly volatile
Other Current Assets476.8 K832 K423.4 K
Slightly volatile
Other Stockholder Equity88.1 M137.6 M75.6 M
Slightly volatile
Total Liabilities3.1 M1.6 M3.7 M
Slightly volatile
Property Plant And Equipment Gross1.2 M1.2 M427.4 K
Slightly volatile
Total Current Assets12.1 M9.3 M10.4 M
Slightly volatile
Short Term Debt33.2 K35 K202.4 K
Pretty Stable
Common Stock8559003.8 K
Slightly volatile
Other Liabilities21.6 K24.3 K26.5 K
Slightly volatile
Non Currrent Assets Other2.9 KK34.7 K
Very volatile
Preferred Stock Total Equity3.4 M3.2 M4.5 M
Slightly volatile
Property Plant Equipment268.2 K478.4 K266.4 K
Slightly volatile
Net Tangible Assets26.5 M25.2 M13 M
Slightly volatile
Warrants5.2 M4.6 M5.8 M
Slightly volatile
Capital Surpluse86 M134.1 M80.1 M
Slightly volatile
Long Term Investments120 K135 K147 K
Slightly volatile
Net Invested Capital11.8 M7.7 M6.6 M
Slightly volatile
Net Working Capital11.5 M7.7 M6.4 M
Slightly volatile
Capital Lease Obligations33.2 K35 K408.3 K
Slightly volatile
Non Current Liabilities Other282.4 K265.5 K369.5 K
Slightly volatile
Long Term Debt184.8 K207.9 K226.4 K
Slightly volatile
Long Term Debt Total184.8 K207.9 K226.4 K
Slightly volatile

Phio Pharmaceuticals Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization115.8 K184 K109.8 K
Very volatile
Other Operating ExpensesM10.7 M11.2 M
Slightly volatile
Research Development5.7 M6.3 M7.1 M
Slightly volatile
Total Operating ExpensesM10.5 M11.2 M
Slightly volatile
Selling General Administrative4.2 M4.3 M3.7 M
Slightly volatile
Cost Of Revenue174.8 K184 K5.6 M
Slightly volatile
Preferred Stock And Other AdjustmentsM1.9 M3.9 M
Slightly volatile
Interest Income8559007.9 K
Slightly volatile
Non Recurring3.8 M4.2 M4.6 M
Slightly volatile
Reconciled Depreciation117.1 K187 K90.1 K
Slightly volatile
Selling And Marketing Expenses147.2 K165.6 K180.3 K
Slightly volatile

Phio Pharmaceuticals Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation287.9 K303 K921.3 K
Slightly volatile
Begin Period Cash Flow10.7 M11.8 M9.6 M
Slightly volatile
Depreciation115.8 K184 K109.8 K
Very volatile
Capital Expenditures4.8 KK56.5 K
Pretty Stable
End Period Cash Flow10.8 M8.5 M9.3 M
Slightly volatile
Dividends Paid4.9 M4.7 M1.8 M
Slightly volatile
Issuance Of Capital Stock7.5 MM14.2 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio275186272
Very volatile
Stock Based Compensation To Revenue21.5516.4318.8721
Very volatile
Payables Turnover0.270.28016.3556
Slightly volatile
Sales General And Administrative To Revenue212202135
Slightly volatile
Research And Ddevelopement To Revenue94.68184131
Slightly volatile
Cash Per Share3.874.074714 K
Slightly volatile
Capex To Operating Cash Flow4.0E-45.0E-40.0064
Pretty Stable
Days Payables Outstanding1.2 K1.3 K32.4 K
Pretty Stable
Income Quality0.660.99290.8313
Slightly volatile
Current Ratio4.295.7054.9782
Slightly volatile
Graham Number19.7820.826185.8 K
Slightly volatile
Revenue Per Share0.60.63411
Slightly volatile
Debt To Assets0.00360.00370.0836
Slightly volatile
Days Of Payables Outstanding1.2 K1.3 K32.4 K
Pretty Stable
Ebt Per Ebit0.781.0120.9569
Pretty Stable
Quick Ratio4.15.19584.7536
Slightly volatile
Dividend Paid And Capex Coverage Ratio2.3 K2.1 K434
Slightly volatile
Net Income Per E B T0.770.890.9131
Pretty Stable
Cash Ratio3.845.19584.4335
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.111.00051.0137
Slightly volatile
Fixed Asset Turnover0.03180.03350.3688
Slightly volatile
Capital Expenditure Coverage Ratio2.3 K2.1 K434
Slightly volatile
Debt Ratio0.00360.00370.0836
Slightly volatile
Price Sales Ratio275186272
Very volatile
Asset Turnover0.00290.0030.008
Slightly volatile

Phio Pharmaceuticals Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap1.5 M1.6 M3.6 M
Slightly volatile

Phio Fundamental Market Drivers

Forward Price Earnings0.3064
Cash And Short Term Investments8.5 M

Phio Upcoming Events

27th of March 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
27th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Phio Pharmaceuticals Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Phio Pharmaceuticals income statement, its balance sheet, and the statement of cash flows. Phio Pharmaceuticals investors use historical funamental indicators, such as Phio Pharmaceuticals's revenue or net income, to determine how well the company is positioned to perform in the future. Although Phio Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in Phio Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Phio Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Phio Pharmaceuticals Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Phio Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue1.4 M1.5 M
Cost Of Revenue184 K174.8 K
Stock Based Compensation To Revenue 16.43  21.55 
Sales General And Administrative To Revenue 201.77  211.86 
Research And Ddevelopement To Revenue 184.29  94.68 
Capex To Revenue(3.94)(4.14)
Revenue Per Share 0.63  0.60 
Ebit Per Revenue(492.15)(516.75)

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

Additional Information and Resources on Investing in Phio Stock

When determining whether Phio Pharmaceuticals Corp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Phio Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Phio Pharmaceuticals Corp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Phio Pharmaceuticals Corp Stock:
Check out the analysis of Phio Pharmaceuticals Correlation against competitors.
You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Phio Pharmaceuticals. If investors know Phio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Phio Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.52)
Return On Assets
(0.70)
Return On Equity
(1.45)
The market value of Phio Pharmaceuticals Corp is measured differently than its book value, which is the value of Phio that is recorded on the company's balance sheet. Investors also form their own opinion of Phio Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Phio Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Phio Pharmaceuticals' market value can be influenced by many factors that don't directly affect Phio Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Phio Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Phio Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Phio Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.